News Headlines

Leqselvi – FDA Approved for Severe Alopecia Areata

Leqselvi™

In July 2024, the U.S. FDA approved Leqselvi™ (deuruxolitinib) as a treatment for adults with severe alopecia areata. Developed by Sun Pharmaceutical, Leqselvi is the third JAK inhibitor to receive FDA approval for this condition, offering hope to patients experiencing patchy, autoimmune-related hair loss. Commercial release is pending ongoing litigation.